Search

Displaying results 1631 - 1640 of 10000 in total
  1. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  2. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.

    Synonyms: N-(2-Hydroxyethyl)nicotinamide nitrate, N-(2-Hydroxyethyl)nicotinamide nitrate (ester)
  3. Drug

    Chlorquinaldol

    go.drugbank.com/drugs/DB13306
    Approved

    Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552] … Chlorquinaldol was used historically as a topical antiseptic under the trade name Sterosan.

  4. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

    Categories: Antiandrogens, non-steroidal
  5. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  6. Drug

    Natural Killer Cell

    go.drugbank.com/drugs/DB15721
    Investigational

    Other techniques involve using umbilical cord blood (UCB) directly; these NK cells have heterogeneous CD56 expression but are considered suitable for immunotherapy. … Generally, the number of NK cells collected in the peripheral blood mononuclear cell (PBMC) is too low for sufficient potency, and ex vivo expansion is performed.

    Synonyms: NK Cells
  7. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    [A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression. … Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy.

  8. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316] … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.

  9. Drug

    Estradiol benzoate

    go.drugbank.com/drugs/DB13953
    ApprovedVet approvedWithdrawn

    Estradiol benzoate is not currently available in Canada or the US. … As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located

  10. Drug

    N4-Hydroxycytidine

    go.drugbank.com/drugs/DB15660
    Experimental

    [A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable. … [A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation

    Synonyms: 4-N-Hydroxycytidine, N(4)-Hydroxycytidine